EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy



Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy



Diabetes Care 23(1): 30-33



A familial predisposition was proposed to be a determinant of the increased morbidity and mortality from cardiovascular disease in type 1 diabetic patients with diabetic nephropathy. The insertion allele of an insertion/deletion polymorphism in the ACE (ACE/ID) gene seems to protect against coronary heart disease in nondiabetic and diabetic subjects. The aim of the present study was to evaluate these hypotheses in parents of a large group of type 1 diabetic patients with and without diabetic nephropathy. We investigated cardiovascular morbidity and mortality of parents of 163 type 1 diabetic patients with nephropathy and parents of 163 sex- and age-matched normoalbuminuric patients with type 1 diabetes. Kaplan-Meier curves showed that total parental mortality was significantly increased in parents of type 1 diabetic patients with nephropathy (121 of 244 [ approximately 50%] ) as compared with parents of normoalbuminuric type 1 diabetic patients (119 of 269 [approximately 44%]) (P = 0.008 [log-rank test]) partially due to an increase in cardiovascular deaths (48 of 244 [approximately 20%] vs. 42 of 269 [approximately 16%], P<0.05). In addition, more patients with nephropathy, as compared with the normoalbuminuric group, had at least one parent with fatal/nonfatal cardiovascular disease (46% [95% CI 38-54] vs. 36% [28-44], P = 0.05). Fathers of patients homozygous for the I-allele of the ACE/ID polymorphism had significantly less myocardial infarction as compared with other genotypes (P = 0.03), regardless of the nephropathic state of the offspring. Cardiovascular morbidity and early mortality clusters in parents of type 1 diabetic patients with diabetic nephropathy The ACE/ID polymorphism helps explain the increased morbidity from cardiovascular disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 045444646

Download citation: RISBibTeXText

PMID: 10857964

DOI: 10.2337/diacare.23.1.30



Related references

Cardiovascular morbidity and early mortality clusters in parents of IDDM patients with diabetic nephropathy. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 119A, Sept, 1997

Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29(2): 334-339, 2006

Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum 240(): 73-79, 2005

Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31(4): 747-752, 2007

Irbesartan diabetic nephropathy trial , a multicenter collaborative trial of angiotensin II receptor antagonism on renal function, mortality, and morbidity in hypertensive type 2 diabetic patients with nephropathy. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 178A, Sept, 1999

NOS3 894G>T polymorphism is associated with progression of kidney disease and cardiovascular morbidity in type 2 diabetic patients: NOS3 as a modifier gene for diabetic nephropathy?. Kidney & Blood Pressure Research 38(1): 92-98, 2014

Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27(3): 765-769, 2004

Cardiovascular cvd mortality in patients with early diabetic nephropathy. Kidney International 37(1): 241, 1990

Morbidity in relation to stage of diabetic nephropathy in type-2 diabetic patients. Journal of the National Medical Association 95(11): 1042-1047, 2003

Cyclin dependent kinase inhibitor p16 is decreased in cultured skin fibroblasts from type 1 diabetic patients with nephropathy An early marker of diabetic nephropathy. Journal of Investigative Medicine 48(5): 265A, September, 2000

Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. Journal of Clinical Endocrinology and Metabolism 93(4): 1470-1475, 2008

Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrology, Dialysis, Transplantation 22(11): 3235-3239, 2007

Apolipoprotein and cardiovascular disease in Type 2 diabetic patients with and without diabetic nephropathy. Diabetologia 36(5): 438-444, 1993

Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 29(3): 498-503, 2006

Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 36(5): 438-444, 1993